Choose a language and wait for the translated text.
"The Court found that Ceban infringed Novo Nordisk's supplementary protection certificate (SPC) covering semaglutide," the Danish drugmaker said in a statement.
Novo Nordisk wins Dutch court injunction in semaglutide patent infringement case | PharmaVoice
